Mozobil Boosts Stem Cells Before Bone Marrow Transplants

FRIDAY, Dec. 19 (HealthDay News) -- The Genzyme Corp. drug Mozobil (plerixafor) has been approved by the U.S. Food and Drug Administration to boost a person's blood stem cell count before a bone marrow transplant, the agency said in a news release.

A bone marrow transplant is often performed in people with certain forms of cancer -- multiple myeloma and non-Hodgkin's lymphoma. Before getting high doses of chemotherapy or radiation, people with these forms of cancer may be advised to have blood stem cells collected so the cells can be re-infused after the therapy. Mozobil helps increase the number of stem cells before collection.

The most frequent side effects of Mozobil reported during clinical testing included diarrhea, nausea, fatigue, reactions near the injection site, headache, joint pain and dizziness.

More information

The U.S. Food and Drug Administration has more about this drug's approval history.

Join the Discussion
blog comments powered by Disqus
You Might Also Like...
See It, Share It
PHOTO: Kanye West accepts the Vanguard Award onstage during the 2015 MTV Video Music Awards at Microsoft Theater on August 30, 2015 in Los Angeles, California.
Christopher Polk/MTV1415/Getty Images
PHOTO: Director Wes Craven attends the screening of Life Itself at the ArcLight Cinemas, June 26, 2014, in Hollywood, Calif.
Paul Archuleta/FilmMagic/Getty Images
PHOTO: The probable path of Hurricane Fred is seen in a graphic released by the NWS National Hurricane Center, Aug. 31, 2015.
NWS National Hurricane Center